Revolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) insider Mark Goldsmith sold 80,000 shares of the firm's stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $209.20, for a total transaction of $16,736,000.00. Following the completion of the transaction, the insider directly owned 267,330 shares in the company, valued at approximately $55,925,436. The trade was a 23.03% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Revolution Medicines Stock Performance
Shares of NASDAQ RVMD opened at $211.38 on Wednesday. The firm has a 50 day moving average of $190.11 and a 200 day moving average of $146.46. The company has a current ratio of 11.38, a quick ratio of 11.38 and a debt-to-equity ratio of 0.40. The firm has a market capitalization of $45.31 billion, a price-to-earnings ratio of -23.97 and a beta of 1.39. Revolution Medicines, Inc. has a 12-month low of $35.62 and a 12-month high of $220.34.
Revolution Medicines (NASDAQ:RVMD - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported ($3.06) EPS for the quarter, missing analysts' consensus estimates of ($2.04) by ($1.02). During the same quarter last year, the firm earned ($1.31) EPS. On average, research analysts anticipate that Revolution Medicines, Inc. will post -8.82 earnings per share for the current year.
Analyst Ratings Changes
Several research firms have recently commented on RVMD. Oppenheimer restated an "outperform" rating and issued a $230.00 price objective on shares of Revolution Medicines in a research note on Thursday, August 6th. Truist Financial lifted their target price on Revolution Medicines from $210.00 to $231.00 and gave the company a "buy" rating in a research report on Tuesday, August 11th. Royal Bank Of Canada boosted their price target on Revolution Medicines from $182.00 to $203.00 and gave the company an "outperform" rating in a report on Thursday, August 6th. HC Wainwright restated a "buy" rating and issued a $195.00 price target on shares of Revolution Medicines in a research report on Monday, July 6th. Finally, Needham & Company LLC raised their price objective on Revolution Medicines from $236.00 to $240.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $167.89.
Check Out Our Latest Stock Analysis on RVMD
Hedge Funds Weigh In On Revolution Medicines
Hedge funds have recently modified their holdings of the company. Contravisory Investment Management Inc. purchased a new stake in shares of Revolution Medicines in the second quarter worth $32,000. ABS Investment Management LLC purchased a new position in shares of Revolution Medicines during the 2nd quarter valued at $337,104,000. Johnson Financial Group Inc. purchased a new position in shares of Revolution Medicines during the 2nd quarter valued at $37,000. Northwestern Mutual Wealth Management Co. purchased a new position in shares of Revolution Medicines during the 2nd quarter valued at $41,000. Finally, Silvant Capital Management LLC bought a new position in Revolution Medicines in the 2nd quarter worth $41,000. 94.34% of the stock is currently owned by institutional investors.
Revolution Medicines Company Profile
(
Get Free Report)
Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company's research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.
The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
